MARKET

SCYX

SCYX

Scynexis
NASDAQ
0.7600
-0.0590
-7.20%
After Hours: 0.7638 +0.0038 +0.50% 16:59 07/15 EDT
OPEN
0.8078
PREV CLOSE
0.8190
HIGH
0.8250
LOW
0.7450
VOLUME
305.39K
TURNOVER
--
52 WEEK HIGH
2.290
52 WEEK LOW
0.6600
MARKET CAP
29.66M
P/E (TTM)
-1.3669
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SCYX last week (0707-0711)?
Weekly Report · 1d ago
Weekly Report: what happened at SCYX last week (0630-0704)?
Weekly Report · 07/07 09:36
SCYNEXIS Holds Annual Meeting, Re-elects Directors
TipRanks · 07/01 20:41
Weekly Report: what happened at SCYX last week (0623-0627)?
Weekly Report · 06/30 09:38
SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price
TipRanks · 06/26 20:37
SCYNEXIS Announces Nasdaq Noncompliance Letter
Benzinga · 06/26 20:04
Weekly Report: what happened at SCYX last week (0616-0620)?
Weekly Report · 06/23 09:36
Weekly Report: what happened at SCYX last week (0609-0613)?
Weekly Report · 06/16 09:38
More
About SCYX
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Webull offers SCYNEXIS Inc stock information, including NASDAQ: SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.